Ratings
0
Nobody has rated this yet. Be the first!
Works
4
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
